Richard Allan Davies

Position

Senior Engineer, Senior lab manager Broegelmann Research Laboratory

Affiliation

Work

Richard is the senior laboratory manager for the Broegelmann Research Laboratory (BRL). His task including work closely with students, researchers and group leaders within the laboratory, assisting with operational tasks and the research school (Bergen Research School of Inflammation).

Originally from New Zealand and finishing his PhD in 2017 at the BRL at the University of Bergen, Norway under the supervision of Prof. Silke Appel, Petra Vogelsang (PhD) and Prof. Roland Jonsson, which was followed by a postdoctoral period under Prof. Stephanie Le Hellard. Background in immunology with extensive experience in immunological laboratory methods, cell culture, method development and optimization, flow and mass cytometry.

Richard works closely with the Head of BRL, Prof. Helena Erlandsson Harris and is part of the Harris group with projects focused on expanding the molecular knowledge of the immune mechanisms active in JIA as a basis for biomarker and therapy development and the alarmin HMGB1. 

Additional Richard has projects from his postdoctoral under the framework of NORMENT with Prof. Stephanie Le Hellard aiming at characterizing endocannabinoid system associated immune cell signalling networks in schizophrenia patients as well as examining skews of peripheral blood immune cells within these patients.

 

Publications
2023
2022
2021
2019

See a complete overview of publications in Cristin.

Projects

Perturbations of the Endocannabinoid system in immune cell signaling networks in Schizophrenia and inflammation  

Schizophrenia (SCZ), a major psychiatric disorder that affects 1% of the population, is characterized by negative symptoms (e.g. withdrawal, anhedonia), positive symptoms (e.g. hallucinations, delusions) and cognitive deficits. Dysregulation of the immune and endocannabinoid system (ECS) has been implicated in the pathogenesis of SCZ. The use of cannabis is the strongest environmental risk factor for SCZ, with more than 22% of patients with SCZ using cannabis at the time of their first episode of psychosis. While poorer anti-psychotic treatment responses are associated with cannabis users than non-users. The aim of our project is to characterize endocannabinoid system (ECS) associated immune cell signalling networks in cannabis using and non-using SCZ patients. We propose to employ human peripheral blood, mass cytometry and selective agonists of cannabinoid receptors to identify ECS associated immune cell signalling events. The identified ECS associated immune cell signalling network will be characterized in regards to donor phenotype: SCZ patients (cannabis users and non-users) and healthy donors to identify disease specific nodes associated with SCZ and cannabis use and whether altered blood DNA-methylation found in SCZ cannabis users, and inflammatory cytokine production are associated with shifts in the cell signalling landscape. Associations with DNA methylation and the immune cell signalling network will further be investigated through in-vitro exposure of peripheral blood cells to the primary cannabis constituents: phytocannabinoid tetrahydrocannabinol (THC) or cannabidol (CBD).